首页> 中文期刊> 《中国医药科学》 >抗生素和益生菌制剂治疗腹泻型肠易激综合征(IBS-D)的临床研究

抗生素和益生菌制剂治疗腹泻型肠易激综合征(IBS-D)的临床研究

         

摘要

ObjectiveTo investigate the clinical effect of antibiotics and probiotics in treatment for IBS-D. Methods128 patients with IBS-D were selected in hospital from October 2011 to October 2013. According to treatment, the patients were divided into two groups. 64 patients treated probiotics as control group. 64 patients treated antibiotics and probiotics as observation group. Course of treatment was 8 weeks. Symptom scores were finished in different time points before and after treatment. Therapeutic effect was compared between two groups. Results Symptom scores at 2 weeks,4 weeks,6 weeks,8 weeks in observation group were significantly lower than control group. Total efficiency in observation group(98.44%) was significantly higher than control group(87.50%). Differences were statistically significant(P<0.05).Conclusion Antibiotics and probiotics are effective drugs in treatment for IBS-D, which can significantly improve clinical symptoms and improve therapeutic effect.%目的:探讨抗生素和益生菌制剂治疗腹泻型肠易激综合征的临床效果。方法选取本院2011年10月~2013年10月诊治的腹泻型肠易激综合征患者128例,根据治疗方案分为两组,64例患者采用益生菌制剂治疗为对照组,64例患者采用抗生素和益生菌制剂治疗为观察组,疗程8周,在治疗前后不同时间点给予患者症状评分,比较两组患者的治疗效果。结果观察组患者在治疗2周、4周、6周、8周时症状评分均明显低于对照组,观察组患者总有效率(98.44%)明显高于对照组(87.50%),差异均有统计学意义(P<0.05)。结论抗生素和益生菌制剂是治疗腹泻型肠易激综合征的有效药物,可明显改善患者的临床病症,显著提高疾病的治疗效果。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号